Key result
Biosafety materials combined with the CRISPR/Cas system show significant potential for the rapid diagnosis and targeted treatment of infectious diseases, though clinical applications remain in early stages.
Why the study?
Recent viral outbreaks highlighted a lack of accurate and timely diagnosis and treatment technologies affecting global biosecurity.
Biosafety materials combined with CRISPR/Cas systems offer promising platforms for the rapid diagnosis and targeted treatment of infectious diseases, though in vivo delivery and off-target effects remain key challenges.
May support CRISPR platforms for infection diagnosis and therapy; leaves open in vivo delivery and off-target risks for clinical translation.
Despite multiple virus outbreaks over the past decade, including the devastating coronavirus disease 2019 (COVID-19) pandemic, the lack of accurate and timely diagnosis and treatment technologies has wreaked havoc on global biosecurity. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated proteins (Cas) system has the potential to address these critical needs for tackling infectious diseases to detect viral nucleic acids and inhibit viral replication. This review summarizes how the CRISPR/Cas system is being utilized for the treatment and diagnosis of infectious diseases with the help of biosafety materials and highlights the design principle and in vivo and in vitro efficacy of advanced biosafety materials used to deal with virus attacks.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a review in Infectious diseases. Biosafety materials and CRISPR/Cas system was evaluated. Biosafety materials combined with the CRISPR/Cas system show significant potential for the rapid diagnosis and targeted treatment of infectious diseases, though clinical applications remain in early stages.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: